Current challenges in managing comorbid heart failure and COPD

References

• Vetrano DL, Palmer K, Marengoni A, et al. Frailty and multimorbidity: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. 2018 May 3.
   PubMed Web of Science ®Google Scholar
• Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3:7–11.
   PubMedGoogle Scholar
• Coronel R, De Groot JR, van Lieshout JJ. Defining heart failure. Cardiovasc Res. 2001;50:419–422.
   PubMed Web of Science ®Google Scholar
• Dubé B-P, Agostoni P, Laveneziana P. Exertional dyspnoea in chronic heart failure: the role of the lung and respiratory mechanical factors. Eur Respir Rev. 2016;25:317–332.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62:e147–239.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–61.
   PubMed Web of Science ®Google Scholar
• Rutten FH, Cramer M-JM, Lammers J-WJ, et al. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail. 2006;8:706–711.
   PubMed Web of Science ®Google Scholar
• Maclay JD, MacNee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013;143:798–807.
   PubMed Web of Science ®Google Scholar
• Oliveira MF, Zelt JTJ, Jones JH, et al. Does impaired O2 delivery during exercise accentuate central and peripheral fatigue in patients with coexistent COPD-CHF? Front Physiol. 2014;5:514.
   PubMed Web of Science ®Google Scholar
• Baldwin ED, Cournand A, Richards DW. Pulmonary insufficiency; a study of 122 cases of chronic pulmonary emphysema. Medicine. 1949;28:201–237.
   PubMed Web of Science ®Google Scholar
• Lazzarini V, Mentz RJ, Fiuzat M, et al. Heart failure in elderly patients: distinctive features and unresolved issues. Eur J Heart Fail. 2013;15:717–723.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013 ;15:347–365.
   Google Scholar
• Roversi S, Fabbri LM, Sin DD, et al. Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care. Am J Respir Crit Care Med. 2016;1:1319–1336.
   Google Scholar
• Iversen KK, Kjaergaard J, Akkan D, et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med. 2008;264:361–369.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Salekin D, Pan D, et al. This patient is not breathing properly: is this COPD, heart failure, or neither? Expert Rev Cardiovasc Ther. 2017;15:389–396.
   PubMed Web of Science ®Google Scholar
• Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;21(364):709–721.
   Google Scholar
• Milic-Emili J. Expiratory flow limitation: Roger S. Mitchell lecture. Chest. 2000;117:219S–23S.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Elbehairy AF, Berton DC, et al. Advances in the evaluation of respiratory pathophysiology during exercise in chronic lung diseases. Front Physiol. 2017;8:82.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Laveneziana P, Webb K, et al. Chronic obstructive pulmonary disease: clinical integrative physiology. Clin Chest Med. 2014;35:51–69.
   PubMed Web of Science ®Google Scholar
• Langer D, Ciavaglia CE, Neder JA, et al. Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment. Expert Rev Respir Med.  2014;8:731-749.
   Web of Science ®Google Scholar
• Langer D, Ciavaglia CE, Faisal A, et al. Inspiratory muscle training reduces diaphragm activation and dyspnea during exercise in COPD. J Appl Physiol. 2018;125:381-392.
   Web of Science ®Google Scholar
• Ribeiro JP, Chiappa GR, Neder JA, et al. Respiratory muscle function and exercise intolerance in heart failure. Curr Heart Fail Rep. 2009;(6):95–101.
   PubMedGoogle Scholar
• Agostoni P, Cattadori G, Bussotti M, et al. Cardiopulmonary interaction in heart failure. Pulm Pharmacol Ther. 2007;20:130–134.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Canepa M, Zambito PE, et al. What can we learn from pulmonary function testing in heart failure? Eur J Heart Fail. 2017;19:1222–1229.
   PubMed Web of Science ®Google Scholar
• Apostolo A, Giusti G, Gargiulo P, et al. Lungs in heart failure. Pulm Med. 2012;2012:952741.
   PubMedGoogle Scholar
• Wasserman K, Zhang YY, Gitt A, et al. Lung function and exercise gas exchange in chronic heart failure. Circulation. 1997;7:2221–2227.
   Google Scholar
• Olson TP, Denzer DL, Sinnett WL, et al. Prognostic value of resting pulmonary function in heart failure. Clin Med Insights Circ Respir Pulm Med. 2013;7:35–43.
   PubMedGoogle Scholar
• Souza AS, Sperandio PA, Mazzuco A, et al. Influence of heart failure on resting lung volumes in patients with COPD. J Bras Pneumol. 2016;42:273–278.
   PubMed Web of Science ®Google Scholar
• Agostoni P, Pellegrino R, Conca C, et al. Exercise hyperpnea in chronic heart failure: relationships to lung stiffness and expiratory flow limitation. J Appl Physiol. 2002;92:1409–1416.
   PubMed Web of Science ®Google Scholar
• Hosenpud JD, Stibolt TA, Atwal K, et al. Abnormal pulmonary function specifically related to congestive heart failure: comparison of patients before and after cardiac transplantation. Am J Med. 1990;88:493–496.
   PubMed Web of Science ®Google Scholar
• Ries AL, Gregoratos G, Friedman PJ, et al. Pulmonary function tests in the detection of left heart failure: correlation with pulmonary artery wedge pressure. Respiration. 1986;49:241–250.
   PubMed Web of Science ®Google Scholar
• Olson TP, Beck KC, Johnson BD. Pulmonary function changes associated with cardiomegaly in chronic heart failure. J Card Fail. 2007;13:100–107.
   PubMed Web of Science ®Google Scholar
• Kelley RC, Ferreira LF. Diaphragm abnormalities in heart failure and aging: mechanisms and integration of cardiovascular and respiratory pathophysiology. Heart Fail Rev. 2017;22:191–207.
   PubMed Web of Science ®Google Scholar
• Torchio R, Gulotta C, Greco-Lucchina P, et al. Closing capacity and gas exchange in chronic heart failure. Chest. 2006;129:1330–1336.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Guenette JA, Maltais F, et al. Decline of resting inspiratory capacity in COPD: the impact on breathing pattern, dyspnea, and ventilatory capacity during exercise. Chest. 2012;141:753–762.
   PubMed Web of Science ®Google Scholar
• Chase SC, Taylor BJ, Cross TJ, et al. Influence of thoracic fluid compartments on pulmonary congestion in chronic heart failure. J Card Fail. 2017;23:690–696.
   PubMed Web of Science ®Google Scholar
• Chase SC, Fermoyle CC, Wheatley CM, et al. The effect of diuresis on extravascular lung water and pulmonary function in acute decompensated heart failure. ESC Heart Fail. 2018;5:364–371.
   PubMed Web of Science ®Google Scholar
• Brenner S, Güder G, Berliner D, et al. Airway obstruction in systolic heart failure–COPD or congestion? Int J Cardiol. 2013;3(168):1910–1916.
   Google Scholar
• Wiener-Kronish JP, Broaddus VC. Interrelationship of pleural and pulmonary interstitial liquid. Annu Rev Physiol. 1993;55:209–226.
   PubMed Web of Science ®Google Scholar
• Clark AL, Cleland JGF. Causes and treatment of oedema in patients with heart failure. Nat Rev Cardiol. 2013;10:156–170.
   PubMed Web of Science ®Google Scholar
• Brenner S, Christa M, Berliner D, et al. Frequency and prognostic impact of mid-expiratory flow reduction in stable patients six months after hospitalisation for heart failure with reduced ejection fraction. Int J Cardiol. 2017;15:727–733.
   Google Scholar
• Agostoni P, Bussotti M, Cattadori G, et al. Gas diffusion and alveolar-capillary unit in chronic heart failure. Eur Heart J. 2006;27:2538–2543.
   PubMed Web of Science ®Google Scholar
• Wright RS, Levine MS, Bellamy PE, et al. Ventilatory and diffusion abnormalities in potential heart transplant recipients. Chest. 1990;98:816–820.
   PubMed Web of Science ®Google Scholar
• Woods PR, Olson TP, Frantz RP, et al. Causes of breathing inefficiency during exercise in heart failure. J Card Fail. 2010;16:835–842.
   PubMed Web of Science ®Google Scholar
• Poon C-S, Tin C. Mechanism of augmented exercise hyperpnea in chronic heart failure and dead space loading. Respir Physiol Neurobiol. 2013;1:114–130.
   Google Scholar
• O’Donnell DE, Neder JA, Elbehairy AF. Physiological impairment in mild COPD. Respirology. 2016 ;21:211–223.
   PubMed Web of Science ®Google Scholar
• Cooper BG, Stocks J, Hall GL, et al. The Global Lung Function Initiative (GLI) network: bringing the world’s respiratory reference values together. Breathe (Sheff). 2017;13:e56–64.
   PubMedGoogle Scholar
• Minasian AG, van den Elshout FJJ, Dekhuijzen PNR, et al. COPD in chronic heart failure: less common than previously thought? Heart Lung. 2013;42:365–371.
   PubMed Web of Science ®Google Scholar
• Güder G, Brenner S, Störk S, et al. Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment. Eur J Heart Fail. 2014;16:1273–1282.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Ciavaglia CE, Neder JA. When obesity and chronic obstructive pulmonary disease collide. Physiological and clinical consequences. Ann Am Thorac Soc. 2014;11:635–644.
   PubMedGoogle Scholar
• Pirina P, Martinetti M, Spada C, et al. Prevalence and management of COPD and heart failure comorbidity in the general practitioner setting. Respir Med. 2017;131:1–5.
   PubMed Web of Science ®Google Scholar
• Güder G, Rutten FH, Brenner S, et al. The impact of heart failure on the classification of COPD severity. J Card Fail. 2012;18:637–644.
   PubMed Web of Science ®Google Scholar
• Minasian AG, van den Elshout FJ, Dekhuijzen PR, et al. Serial pulmonary function tests to diagnose COPD in chronic heart failure. Transl Respir Med. 2014;12(2):Dec.
   Google Scholar
• Rocha A, Arbex FF, Sperandio PA, et al., Excess ventilation in COPD-heart failure overlap: implications for dyspnea and exercise intolerance. Am J Respir Crit Care Med. 2017 ;196:1264-1274.
   Google Scholar
• O’Donnell DE, Elbehairy AF, Faisal A, et al. Exertional dyspnoea in COPD: the clinical utility of cardiopulmonary exercise testing. Eur Respir Rev. 2016;25:333–347.
   PubMed Web of Science ®Google Scholar
• Guazzi M, Bandera F, Ozemek C, et al. Cardiopulmonary exercise testing: what is its value? J Am Coll Cardiol. 2017;26:1618–1636.
   Google Scholar
• Arena R, Sietsema KE. Cardiopulmonary exercise testing in the clinical evaluation of patients with heart and lung disease. Circulation. 2011;15(123):668–680.
   Google Scholar
• Corrà U. Exercise oscillatory ventilation in heart failure. Int J Cardiol. 2016;206 Suppl:S13-5.
   Web of Science ®Google Scholar
• Johnson BD, Beck KC, Olson LJ, et al. Ventilatory constraints during exercise in patients with chronic heart failure. Chest. 2000;117:321–332.
   PubMed Web of Science ®Google Scholar
• Hansen JE, Ulubay G, Chow BF, et al. Mixed-expired and end-tidal CO2 distinguish between ventilation and perfusion defects during exercise testing in patients with lung and heart diseases. Chest. 2007;132:977–983.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Corrà U, Agostoni P. Cardiopulmonary exercise testing in patients with heart failure with specific comorbidities. Ann Am Thorac Soc. 2017;14:S110–5.
   PubMed Web of Science ®Google Scholar
• Arbex FF, Alencar MC, Souza A, et al. Exercise ventilation in COPD: influence of systolic heart failure. COPD. 2016;13:693-699.
   Google Scholar
• Oliveira MF, Arbex F, Alencar MC, et al. Heart failure impairs muscle blood flow and endurance exercisetolerance in COPD. COPD. 2016;13:407-415.
   Google Scholar
• Apostolo A, Laveneziana P, Palange P, et al. Impact of chronic obstructive pulmonary disease on exercise ventilatory efficiency in heart failure. Int J Cardiol. 2015;15:134–140.
   Google Scholar
• Alencar MC, Arbex F, O’Donnell DE, et al. Does exercise ventilatory inefficiency predict poor outcome in heart failure patients with COPD? J Cardiopulm Rehab Prev. 2016;36:454-459.
   PubMed Web of Science ®Google Scholar
• Rocha A, Arbex FF, Alencar MCN, et al. Physiological and sensory consequences of exercise oscillatory ventilation in heart failure-COPD. Int J Cardiol. 2016;24:447–453.
   Google Scholar
• Mahler DA, O’Donnell DE. Recent advances in dyspnea. Chest. 2015;147:232–241.
   PubMed Web of Science ®Google Scholar
• Oliveira MF, Arbex F, Alencar MCN, et al. Heart failure impairs cerebral oxygenation during exercise in patients with COPD. Eur Respir J. 2013;42:1423–1426.
   PubMedGoogle Scholar
• Oliveira MF, Alencar MC, Arbex F, et al. Effects of heart failure on cerebral blood flow in COPD: rest and exercise. Respir Physiol Neurobiol. 2016;15:41–48.
   Google Scholar
• Treptow E, Oliveira MF, Soares A, et al. Cerebral microvascular blood flow and CO2 reactivity in pulmonary arterial hypertension. Respir Physiol Neurobiol. 2016;233:60–65.
   PubMed Web of Science ®Google Scholar
• Olson TP, Joyner MJ, Johnson BD. Influence of locomotor muscle metaboreceptor stimulation on the ventilatory response to exercise in heart failure. Circ Heart Fail. 2010; 3:212–219.
   PubMed Web of Science ®Google Scholar
• Hirai DM, Musch TI, Poole DC. Exercise training in chronic heart failure: improving skeletal muscle O2 transport and utilization. Am J Physiol Heart Circ Physiol. 2015;309:H1419-39.
   Web of Science ®Google Scholar
• Floras JS, Ponikowski P. The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. Eur Heart J. 2015;7:1974–1982b.
   Google Scholar
• Leitao Filho FS, Alotaibi NM, Yamasaki K, et al. The role of beta-blockers in the management of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2018;12:125–135.
   PubMed Web of Science ®Google Scholar
• Mohammed J, Meeus M, Derom E, et al. Evidence for autonomic function and its influencing factors in subjects with COPD: a systematic review. Respir Care. 2015;60:1841–1851.
   PubMed Web of Science ®Google Scholar
• Matera MG, Martuscelli E, Cazzola M. Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Pulm Pharmacol Ther. 2010;23:1–8.
   PubMed Web of Science ®Google Scholar
• Hawkins NM, Petrie MC, Macdonald MR, et al. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists. J Am Coll Cardiol. 2011;24:2127–2138.
   Google Scholar
• Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J. 2013;34:2795–2803.
   PubMed Web of Science ®Google Scholar
• Agostoni P, Palermo P, Contini M. Respiratory effects of beta-blocker therapy in heart failure. Cardiovasc Drugs Ther. 2009;23:377–384.
   PubMed Web of Science ®Google Scholar
• Mentz RJ, Wojdyla D, Fiuzat M, et al. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol. 2013;15:582–587.
   Google Scholar
• Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;27:1780–1787.
   Google Scholar
• Agostoni P, Contini M, Cattadori G, et al. Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? Eur J Heart Fail. 2007;9:827–833.
   PubMed Web of Science ®Google Scholar
• Magrì D, Palermo P, Cauti FM, et al. Chronotropic incompentence and functional capacity in chronic heart failure: no role of beta-blockers and beta-blocker dose. Cardiovasc Ther. 2012;30:100–108.
   PubMed Web of Science ®Google Scholar
• Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2018;15;378:684–685.
   Google Scholar
• Chen HH, Schrier RW. Pathophysiology of volume overload in acute heart failure syndromes. Am J Med. 2006;119:S11–16.
   PubMed Web of Science ®Google Scholar
• Lorenzi-Filho G, Azevedo ER, Parker JD, et al. Relationship of carbon dioxide tension in arterial blood to pulmonary wedge pressure in heart failure. Eur Respir J. 2002;19:37–40.
   PubMed Web of Science ®Google Scholar
• Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;21:217–227.
   Google Scholar
• Aaron CP, Hoffman EA, Lima JAC, et al. Pulmonary vascular volume, impaired left ventricular filling and dyspnea: the MESA lung study. PLoS One. 2017;12:e0176180.
   PubMed Web of Science ®Google Scholar
• Barr RG. Rethinking chronic obstructive pulmonary disease. Chronic pulmonary insufficiency and combined cardiopulmonary insufficiency. Ann Am Thorac Soc. 2018;15:S30–4.
   PubMed Web of Science ®Google Scholar
• Hill NS. Fluid and electrolyte considerations in diuretic therapy for hypertensive patients with chronic obstructive pulmonary disease. Arch Intern Med. 1986;146:129–133.
   PubMedGoogle Scholar
• Hypokalaemia induced by inhalation of fenoterol. - PubMed - NCBI [Internet]. [cited 2018 May 15]. Available from: https://www-ncbi-nlm-nih-gov.proxy.queensu.ca/pubmed/2860336
   Google Scholar
• Brijker F, Heijdra YF, van den Elshout FJJ, et al. Discontinuation of furosemide decreases PaCO(2) in patients with COPD. Chest. 2002;121:377–382.
   PubMed Web of Science ®Google Scholar
• Prieto de Paula JM, Franco Hidalgo S, Borge Gallardo L, et al. The importance of identifying the association between metabolic alkalosis and respiratory acidosis. Arch Bronconeumol. 2012;48:65–66.
   PubMed Web of Science ®Google Scholar
• Palange P. Renal and hormonal abnormalities in chronic obstructive pulmonary disease (COPD). Thorax. 1998;53:989–991.
   PubMed Web of Science ®Google Scholar
• Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of congestive state in chronic obstructive pulmonary disease. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery. Circulation. 1992;86:12–21.
   PubMed Web of Science ®Google Scholar
• von Lueder TG, Sangaralingham SJ, Wang BH, et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail. 2013;6:594–605.
   PubMed Web of Science ®Google Scholar
• Marshall RP. The pulmonary renin-angiotensin system. Curr Pharm Des. 2003;9:715–722.
   PubMed Web of Science ®Google Scholar
• Parikh MA, Aaron CP, Hoffman EA, et al. Angiotensin-converting inhibitors and angiotensin II receptor blockers and longitudinal change in percent emphysema on computed tomography. The multi-ethnic study of atherosclerosis lung study. Ann Am Thorac Soc. 2017;14:649–658.
   PubMed Web of Science ®Google Scholar
• Petersen H, Sood A, Meek PM, et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. Chest. 2014;145:695–703.
   PubMed Web of Science ®Google Scholar
• Mancini GBJ, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;20:2554–2560.
   Google Scholar
• Sebastian JL, McKinney WP, Kaufman J, et al. Angiotensin-converting enzyme inhibitors and cough. Prevalence in an outpatient medical clinic population. Chest. 1991;99:36–39.
   PubMed Web of Science ®Google Scholar
• Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:169S–173S.
   PubMed Web of Science ®Google Scholar
• Guazzi M, Melzi G, Marenzi GC, et al. Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction. Clin Pharmacol Ther. 1999;65:319–327.
   PubMed Web of Science ®Google Scholar
• Guazzi M, Palermo P, Pontone G, et al. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. Am J Cardiol. 1999 ;1:1038–1043.
   Google Scholar
• Guazzi M, Agostoni P, Guazzi MD. Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure. J Am Coll Cardiol. 2001;37:398–406.
   PubMed Web of Science ®Google Scholar
• Di Marco F, Guazzi M, Vicenzi M, et al. Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: A pilot study. Pulm Pharmacol Ther. 2010;23:159–164.
   PubMed Web of Science ®Google Scholar
• Contini M, Compagnino E, Cattadori G, et al. ACE-inhibition benefit on lung function in heart failure is modulated by ACE insertion/deletion polymorphism. Cardiovasc Drugs Ther. 2016;30:159–168.
   PubMed Web of Science ®Google Scholar
• Jjv M, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;11:993–1004.
   Google Scholar
• de Man FS, Tu L, Handoko ML, et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;15:780–789.
   Google Scholar
• Domenig O, Manzel A, Grobe N, et al. Neprilysin is a mediator of alternative renin-angiotensin-system activation in the murine and human kidney. Sci Rep. 2016;21:33678.
   Google Scholar
• Shenoy V, Ferreira AJ, Qi Y, et al. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 2010;182:1065–1072.
   PubMed Web of Science ®Google Scholar
• Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004; 11:2049–2057.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Archibald DG, Francis GS, et al. Veterans administration cooperative study on vasodilator therapy of heart failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Circulation. 1987;75:IV49–54.
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Peter RH. Hemodynamics at rest and during exercise after oral hydralazine in patients with cor pulmonale. Am J Cardiol. 1981;47:116–122.
   PubMed Web of Science ®Google Scholar
• Lupi-Herrera E, Seoane M, Verdejo J. Hemodynamic effect of hydralazine in advanced, stable chronic obstructive pulmonary disease with cor pulmonale. Immediate and short-term evaluation at rest and during exercise. Chest. 1984;85:156–163.
   PubMed Web of Science ®Google Scholar
• Brent BN, Berger HJ, Matthay RA, et al. Contrasting acute effects of vasodilators (nitroglycerin, nitroprusside, and hydralazine) on right ventricular performance in patients with chronic obstructive pulmonary disease and pulmonary hypertension: a combined radionuclide-hemodynamic study. Am J Cardiol. 1983;51:1682–1689.
   PubMed Web of Science ®Google Scholar
• Hori M, Okamoto H. Heart rate as a target of treatment of chronic heart failure. J Cardiol. 2012 ;60:86–90.
   PubMed Web of Science ®Google Scholar
• Jensen MT, Marott JL, Lange P, et al. Resting heart rate is a predictor of mortality in COPD. Eur Respir J. 2013;42:341–349.
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Swedberg K, Komajda M, et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol. 2013;10:182–188.
   Google Scholar
• Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;21:1831–1838.
   Google Scholar
• Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;19:871–878.
   Google Scholar
• Guazzi M, Gatto P, Giusti G, et al. Pathophysiology of cardiorenal syndrome in decompensated heart failure: role of lung-right heart-kidney interaction. Int J Cardiol. 2013;30:379–384.
   Google Scholar
• Dudgeon D, Baracos VE. Physiological and functional failure in chronic obstructive pulmonary disease, congestive heart failure and cancer: a debilitating intersection of sarcopenia, cachexia and breathlessness. Curr Opin Support Palliat Care. 2016;10:236–241.
   PubMed Web of Science ®Google Scholar
• Goudis CA, Konstantinidis AK, Ntalas IV, et al. Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease. Int J Cardiol. 2015;15:264–273.
   Google Scholar
• Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology foundation/American Heart Association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2013;61:e6–75.
   PubMed Web of Science ®Google Scholar
• Bilchick KC, Stukenborg GJ, Kamath S, et al. Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2012;23:1647–1655.
   Google Scholar
• Granfeldt A, Wissenberg M, Hansen SM, et al. Severity of chronic obstructive pulmonary disease and presenting rhythm in patients with out-of-hospital cardiac arrest. Resuscitation. 2018;126:111–117.
   PubMed Web of Science ®Google Scholar
• Naksuk N, Kunisaki KM, Benditt DG, et al. Implantable cardioverter-defibrillators in patients with COPD. Chest. 2013;144:778–783.
   PubMed Web of Science ®Google Scholar
• Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008 ;8:1357–1365.
   Google Scholar
• Barold SS, Herweg B. Cardiac resynchronization in patients with atrial fibrillation. J Atr Fibrillation. 2015;8:1383.
   PubMedGoogle Scholar
• Kirubakaran S, Ladwiniec A, Arujuna A, et al. Male gender and chronic obstructive pulmonary disease predict a poor clinical response in patients undergoing cardiac resynchronisation therapy. Int J Clin Pract. 2011;65:281–288.
   PubMed Web of Science ®Google Scholar
• Laveneziana P, O’Donnell DE, Ofir D, et al. Effect of biventricular pacing on ventilatory and perceptual responses to exercise in patients with stable chronic heart failure. J Appl Physiol. 2009;106:1574–1583.
   PubMed Web of Science ®Google Scholar
• Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events: a cohort analysis. Am J Respir Crit Care Med. 2018;198:51-57.
   Google Scholar
• Miravitlles M, D’Urzo A, Singh D, et al. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res. 2016;17:112.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful? Chest. 2000;117:42S–7S.
   PubMed Web of Science ®Google Scholar
• Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6:368–378.
   PubMed Web of Science ®Google Scholar
• Dempsey JA, Romer L, Rodman J, et al. Consequences of exercise-induced respiratory muscle work. Respir Physiol Neurobiol. 2006;28:242–250.
   Google Scholar
• Borghi-Silva A, Carrascosa C, Oliveira CC, et al. Effects of respiratory muscle unloading on leg muscle oxygenation and blood volume during high-intensity exercise in chronic heart failure. Am J Physiol Heart Circ Physiol. 2008;294:H2465–2472.
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Calzetta L, et al. Safety considerations with dual bronchodilator therapy in copd: an update. Drug Saf. 2016;39:501–508.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Enright P, et al. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax. 2013;68:114–116.
   PubMed Web of Science ®Google Scholar
• Taylor BJ, Snyder EM, Richert ML, et al. Effect of beta2-adrenergic receptor stimulation on lung fluid in stable heart failure patients. J Heart Lung Transplant. 2017;36:418–426.
   PubMed Web of Science ®Google Scholar
• Chase SC, Wheatley CM, Olson LJ, et al. Impact of chronic systolic heart failure on lung structure-function relationships in large airways. Physiol Rep. 2016;4. pii: e12867.
   Google Scholar
• Stone IS, Barnes NC, James W-Y, et al. Lung deflation and cardiovascular structure and function in chronic obstructive pulmonary disease. A randomized controlled trial. Am J Respir Crit Care Med. 2016;193:717–726.
   PubMed Web of Science ®Google Scholar
• Segreti A, Fiori E, Calzetta L, et al. The effect of indacaterol during an acute exacerbation of COPD. Pulm Pharmacol Ther. 2013;26:630–634.
   PubMed Web of Science ®Google Scholar
• Cosentino ER, Degli Esposti D, Miceli R, et al. Coexisting heart failure and chronic obstructive pulmonary disease: report of two cases treated with indacaterol/glycopyrronium. Respiration. 2018;95:3–5.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Matera MG, et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable chronic obstructive pulmonary disease. Chest. 2016;149:1181–1196.
   PubMed Web of Science ®Google Scholar
• Rinaldi B, Donniacuo M, Sodano L, et al. Effects of chronic treatment with the new ultra-long-acting beta2-adrenoceptor agonist indacaterol alone or in combination with the beta1-adrenoceptor blocker metoprolol on cardiac remodelling. Br J Pharmacol. 2015;172:3627–3637.
   PubMed Web of Science ®Google Scholar
• Gavaldà A, Ramos I, Carcasona C, et al. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. Pulm Pharmacol Ther. 2014;28:114–121.
   PubMed Web of Science ®Google Scholar
• Dumitru L, Iliescu A, Dinu H, et al. Disability in COPD and chronic heart failure is the skeletal muscle the final common pathway? Maedica (Buchar). 2013;8:206–213.
   PubMedGoogle Scholar
• Singh D, Barnes PJ, Stockley R, et al. Pharmacological treatment of COPD: the devil is always in the detail. Eur Respir J.  2018;51. pii: 1800263.
   Google Scholar
• Iannella H, Luna C, Waterer G. Inhaled corticosteroids and the increased risk of pneumonia: what’s new? A 2015 updated review. Ther Adv Respir Dis. 2016;10:235–255.
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2018. pii: S0003-9993(18)30234-X.
   Google Scholar
• Janson C, Stratelis G, Miller-Larsson A, et al. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:3055–3064.
   PubMed Web of Science ®Google Scholar
• Leung JM, Sin DD. Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. BMJ. 2017;25;358:j3772.
   Google Scholar
• Molenaar P, Christ T, Hussain RI, et al. PDE3, but not PDE4, reduces beta1- and beta2-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients. Br J Pharmacol. 2013;169:528–538.
   PubMed Web of Science ®Google Scholar
• Eschenhagen T. PDE4 in the human heart - major player or little helper? Br J Pharmacol. 2013 ;169:524–527.
   PubMed Web of Science ®Google Scholar
• Watz H, Bagul N, Rabe KF, et al. Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:813–822.
   PubMed Web of Science ®Google Scholar
• Guo D, Cai Y, Chai D, et al. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010;65:631–640.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Barnes PJ, et al. Efficacy and safety profile of xanthines in COPD: a network meta-analysis. Eur Respir Rev. 2018; 30:27.
   PubMed Web of Science ®Google Scholar
• Cirillo R, Grossi E, Franzone JS. Doxofylline, an adenosine-nonblocking xanthine, does not induce cardiostimulant effects. Res Commun Chem Pathol Pharmacol. 1989;65:21–34.
   PubMedGoogle Scholar
• Dini FL, Pasini G, Cortellini G, et al. Methylxanthine drug therapy in chronic heart failure associated with hypoxaemia: double-blind placebo-controlled clinical trial of doxofylline versus theophylline and bamifylline. Int J Clin Pharmacol Res. 1993;13:305–316.
   PubMedGoogle Scholar
• Bongrani S, Razzetti R, Papotti M, et al. Lack of cardiostimulant effects of bamifylline in in vitro and in vivo models. Arzneimittelforschung. 1990;40:169–174.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Webb KA, Harle I, et al. Pharmacological management of breathlessness in COPD: recent advances and hopes for the future. Expert Rev Respir Med. 2016;10:823–834.
   PubMed Web of Science ®Google Scholar
• Evans RA. Developing the model of pulmonary rehabilitation for chronic heart failure. Chron Respir Dis. 2011;8:259–269.
   PubMed Web of Science ®Google Scholar
• Palmer K, Bowles K-A, Paton M, et al. Chronic heart failure and exercise rehabilitation: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2018 Apr 23.
   PubMed Web of Science ®Google Scholar
• Rochester CL, Vogiatzis I, Holland AE, et al. An official American Thoracic Society/European Respiratory Society policy statement: enhancing implementation, use, and delivery of pulmonary rehabilitation. Am J Respir Crit Care Med. 2015;192:1373–1386.
   PubMed Web of Science ®Google Scholar
• Franssen FME, Rochester CL. Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter? Eur Respir Rev. 2014;23:131–141.
   PubMedGoogle Scholar
• Desveaux L, Harrison S, Lee A, et al. “We are all there for the same purpose”: support for an integrated community exercise program for older adults with HF and COPD. Heart Lung. 2017;46:308–312.
   PubMed Web of Science ®Google Scholar
• Vogiatzis I, Nanas S, Kastanakis E, et al. Dynamic hyperinflation and tolerance to interval exercise in patients with advanced COPD. Eur Respir J. 2004;24:385–390.
   PubMed Web of Science ®Google Scholar
• Tunsupon P, Lal A, Abo Khamis M, et al. Comorbidities in patients with chronic obstructive pulmonary disease and pulmonary rehabilitation outcomes. J Cardiopulm Rehabil Prev. 2017;37:283–289.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Gifford AH, Waterman LA, et al. Mechanism of greater oxygen desaturation during walking compared with cycling in patients with COPD. Chest. 2011;140:351–358.
   PubMed Web of Science ®Google Scholar
• Zacarias EC, Neder JA, Cendom SP, et al. Heart rate at the estimated lactate threshold in patients with chronic obstructive pulmonary disease: effects on the target intensity for dynamic exercise training. J Cardiopulm Rehabil. 2000;20:369–376.
   PubMedGoogle Scholar
• Louvaris Z, Vogiatzis I. Physiological basis of cardiopulmonary rehabilitation in patients with lung or heart disease. Breathe (Sheff). 2015;11:120–127.
   PubMedGoogle Scholar
• Palange P, Forte S, Onorati P, et al. Ventilatory and metabolic adaptations to walking and cycling in patients with COPD. J Appl Physiol. 2000;88:1715–1720.
   PubMed Web of Science ®Google Scholar
• Kortianou EA, Nasis IG, Spetsioti ST, et al. Effectiveness of interval exercise training in patients with COPD. Cardiopulm Phys Ther J. 2010;21:12–19.
   PubMedGoogle Scholar
• Bravo DM, Gimenes AC, Amorim BC, et al. Excess ventilation in COPD: implications for dyspnoea and tolerance to interval exercise. Respir Physiol Neurobiol. 2018;250:7–13.
   PubMed Web of Science ®Google Scholar
• Evans RA, Dolmage TE, Mangovski-Alzamora S, et al. One-legged cycle training for chronic obstructive pulmonary disease. A pragmatic study of implementation to pulmonary rehabilitation. Ann Am Thorac Soc. 2015;12:1490–1497.
   PubMed Web of Science ®Google Scholar
• Neder JA, Sword D, Ward SA, et al. Home based neuromuscular electrical stimulation as a new rehabilitative strategy for severely disabled patients with chronic obstructive pulmonary disease (COPD). Thorax. 2002;57:333–337.
   PubMed Web of Science ®Google Scholar
• Borghi-Silva A, Oliveira CC, Carrascosa C, et al. Respiratory muscle unloading improves leg muscle oxygenation during exercise in patients with COPD. Thorax. 2008;63:910–915.
   PubMed Web of Science ®Google Scholar
• Chiappa GR, Queiroga F, Meda E, et al. Heliox improves oxygen delivery and utilization during dynamic exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179:1004–1010.
   PubMedGoogle Scholar
• Charususin N, Dacha S, Gosselink R, et al. Respiratory muscle function and exercise limitation in patients with chronic obstructive pulmonary disease: a review. Expert Rev Respir Med. 2018;12:67–79.
   PubMed Web of Science ®Google Scholar
• Casaburi R, Patessio A, Ioli F, et al. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis. 1991;143:9–18.
   PubMed Web of Science ®Google Scholar
• Guazzi M, Belletti S, Tumminello G, et al. Exercise hyperventilation, dyspnea sensation, and ergoreflex activation in lone atrial fibrillation. Am J Physiol Heart Circ Physiol. 2004;287:H2899–2905.
   PubMed Web of Science ®Google Scholar
• Morganroth M, Pape G, Rozenfeld Y, et al. Multidisciplinary COPD disease management program: impact on clinical outcomes. Postgrad Med. 2016;128:239–249.
   PubMed Web of Science ®Google Scholar
• Güder G, Störk S, Gelbrich G, et al. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling. Eur J Heart Fail. 2015;17:442–452.
   PubMed Web of Science ®Google Scholar
• Gandhi S, Mosleh W, Sharma UC, et al. Multidisciplinary Heart failure clinics are associated with lower heart failure hospitalization and mortality: systematic review and meta-analysis. Can J Cardiol. 2017;33:1237–1244.
   PubMed Web of Science ®Google Scholar
• Boylan P, Joseph T, Hale G, et al. Chronic obstructive pulmonary disease and heart failure self-management kits for outpatient transitions of care. Consult Pharm. 2018;1:152–158.
   Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680.
   PubMed Web of Science ®Google Scholar